Quantification of Self-Recognition in Multiple Sclerosis by Single-Cell Analysis of Cytokine Production1

Identifying and quantifying autoaggressive responses in multiple sclerosis (MS) has been difficult in the past due to the low frequency of autoantigen-specific T cells, the high number of putative determinants on the autoantigens, and the different cytokine signatures of the autoreactive T cells. We used single-cell resolution enzyme-linked immunospot (ELISPOT) assays to study, directly ex vivo, proteolipid protein (PLP)-specific memory cell reactivity from MS patients and controls. Overlapping 9-aa-long peptides, spanning the entire PLP molecule in single amino acid steps, were used to determine the frequency and fine specificity of PLP-specific lymphocytes as measured by their IFN-γ and IL-5 production. MS patients (n = 22) responded to 4 times as many PLP peptides as did healthy controls (n = 22). The epitopes recognized in individual patients, up to 22 peptides, were scattered throughout the PLP molecule, showing considerable heterogeneity among MS patients. Frequency measurements showed that the number of PLP peptide-specific IFN-γ-producing cells averaged 11 times higher in MS patients than in controls. PLP peptide-induced IL-5-producing T cells occurred in very low frequencies in both MS patients and controls. This first comprehensive assessment of the anti-PLP-Th1/Th2 response in MS shows a greatly increased Th1 effector cell mass in MS patients. Moreover, the highly IFN-γ-polarized, IL-5-negative cytokine profile of the PLP-reactive T cells suggests that these cells are committed Th1 cells. The essential absence of uncommitted Th0 cells producing both cytokines may explain why therapeutic strategies that aim at the induction of immune deviation show little efficacy in the established disease.

[1]  L. Matis,et al.  Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. , 1996, The Journal of clinical investigation.

[2]  T. Owens,et al.  Inflammatory cytokines in the brain: does the CNS shape immune responses? , 1994, Immunology today.

[3]  M. Pender,et al.  Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. , 1997, Brain : a journal of neurology.

[4]  R. Karr,et al.  HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides , 1997, Journal of Neuroimmunology.

[5]  T. Olsson,et al.  Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls , 1991, European journal of immunology.

[6]  N. Sarvetnick,et al.  Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma , 1988, Cell.

[7]  H. M. Geysen,et al.  Strategies for epitope analysis using peptide synthesis. , 1987, Journal of immunological methods.

[8]  H. Kirchner,et al.  Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? , 1988, Acta neurologica Scandinavica.

[9]  V. Tuohy,et al.  Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. , 1999, Journal of autoimmunity.

[10]  E. Sercarz,et al.  T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes , 1991, The Journal of experimental medicine.

[11]  C. Piccirillo,et al.  TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. , 1995, Journal of immunology.

[12]  H. Weiner,et al.  Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis , 1986, Journal of Neuroimmunology.

[13]  H. Weiner,et al.  Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. , 1987, Journal of immunology.

[14]  S. Hauser,et al.  Late Complications of Immune Deviation Therapy in a Nonhuman Primate , 1996, Science.

[15]  P. Lebon,et al.  Multiple sclerosis: Involvement of interferons in lesion pathogenesis , 1988, Annals of neurology.

[16]  F. Finkelman,et al.  Effect of anti-interferon-γ monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains , 1994, Journal of Neuroimmunology.

[17]  T. Olsson,et al.  Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-γ, interleukin-4 and transforming growth factor-β , 1994, Journal of Neuroimmunology.

[18]  E. Sercarz,et al.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen , 1992, Nature.

[19]  H. McFarland,et al.  T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls , 1996, Multiple sclerosis.

[20]  H. McFarland,et al.  T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects , 1998, Journal of Neuroimmunology.

[21]  H. McFarland,et al.  Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. , 1995, Critical reviews in clinical laboratory sciences.

[22]  A. Broocks,et al.  Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis , 1994, Neurology.

[23]  T. Olsson,et al.  Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis , 1992, Journal of Neuroimmunology.

[24]  D. Bourdette,et al.  Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis , 1992, Journal of Neuroimmunology.

[25]  H. McFarland,et al.  Identification of a novel T cell epitope of human proteolipid protein (residues 40–60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients , 1993, Journal of Neuroimmunology.

[26]  R. Kinkel,et al.  Diversity and plasticity of self recognition during the development of multiple sclerosis. , 1997, The Journal of clinical investigation.

[27]  Meijuan Zhao,et al.  Interferon-γ-Induced Oligodendrocyte Cell Death: Implications for the Pathogenesis of Multiple Sclerosis , 1995, Molecular medicine.

[28]  A. Broocks,et al.  Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity , 1995, Annals of neurology.

[29]  V. Tuohy,et al.  Spontaneous Regression of Primary Autoreactivity during Chronic Progression of Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis , 1999, The Journal of experimental medicine.

[30]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[31]  T. Olsson,et al.  Organ‐specific autoantigens induce interferon‐γ and interleukin‐4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis , 1994, Neurology.

[32]  D. Willenborg,et al.  Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation , 1990, Journal of the Neurological Sciences.

[33]  J. Merrill,et al.  Tumor necrosis factor identified in multiple sclerosis brain , 1989, The Journal of experimental medicine.

[34]  Paul V. Lehmann,et al.  Endogenous Myelin Basic Protein Inactivates the High Avidity T Cell Repertoire , 1998, The Journal of experimental medicine.

[35]  A. Tobin,et al.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes , 1993, Nature.

[36]  H. McFarland,et al.  Identification of a second T cell epitore of human proteolipid protein (residues 89–106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients , 1994, Journal of Neuroimmunology.

[37]  A. Sette,et al.  T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans , 1994, Journal of Neuroimmunology.

[38]  N. Calcutt,et al.  Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction , 1995, The Journal of experimental medicine.

[39]  T. Owens,et al.  Interferon‐γ confers resistance to experimental allergic encephalomyelitis , 1996, European journal of immunology.

[40]  J. Link Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. , 1994, Acta neurologica Scandinavica. Supplementum.

[41]  W. Hickey,et al.  Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides , 1991, Journal of Neuroimmunology.

[42]  N. Sarvetnick,et al.  Transgenic mice expressing IFN-gamma in the retina develop inflammation of the eye and photoreceptor loss. , 1994, Investigative ophthalmology & visual science.

[43]  B. Boehm,et al.  Direct Visualization of Cytokine-Producing Recall Antigen-Specific CD4 Memory T Cells in Healthy Individuals and HIV Patients1 , 2000, The Journal of Immunology.

[44]  F. Cardinaux,et al.  In vivo competition between self peptides and foreign antigens in T-cell activation , 1988, Nature.

[45]  I. Cohen,et al.  Shifts in the epitopes of myelin basic protein recognized by Lewis rat T cells before, during, and after the induction of experimental autoimmune encephalomyelitis. , 1993, The Journal of clinical investigation.

[46]  A. Billiau,et al.  Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. , 1988, Journal of immunology.

[47]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.

[48]  B. Uitdehaag,et al.  Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon‐gamma in Lewis rats , 1990, Clinical and experimental immunology.

[49]  A. Bradley,et al.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.

[50]  C. Bever,et al.  Gamma‐interferon induction in patients with chronic progressive MS , 1991, Neurology.

[51]  P. Lehmann,et al.  Induction of TH1 and TH2 Immunity in Neonatal Mice , 1996, Science.

[52]  T. Olsson,et al.  Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. , 1990, The Journal of clinical investigation.

[53]  T. Olsson,et al.  Increased transforming growth factor‐β, interleukin‐4, and interferon‐γ in multiple sclerosis , 1994, Annals of neurology.

[54]  H. Link,et al.  Review: cytokines and the pathogenesis of multiple sclerosis , 1996, Journal of neuroscience research.